PHAXIAM Therapeutics (XPAR:PHXM) ROE % Adjusted to Book Value : 0.00% (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics ROE % Adjusted to Book Value?

PHAXIAM Therapeutics's ROE % for the quarter that ended in Sep. 2023 was -62.13%. PHAXIAM Therapeutics's PB Ratio for the quarter that ended in Sep. 2023 was N/A. PHAXIAM Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was N/A.

PHAXIAM Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for PHAXIAM Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics ROE % Adjusted to Book Value Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-30.36

-38.72

-24.35

-75.65

-2.04

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															125.22	-	210.58	-	-

Competitive Comparison of PHAXIAM Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, PHAXIAM Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PHAXIAM Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's ROE % Adjusted to Book Value falls into.

PHAXIAM Therapeutics ROE % Adjusted to Book Value Calculation

PHAXIAM Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-0.98%	/	0.48
	=	-2.04%

PHAXIAM Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-62.13%	/	N/A
	=	N/A

PHAXIAM Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

PHXM:USA 2E41:Germany

Address

60 Avenue Rockefeller, Lyon, FRA, 69008

Website

https://www.erytech.com

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.